Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 574 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Male Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

NCT06397872
View directory record Official record
Conditions
Renal Impairment
Interventions
100 mg Resmetirom Tablet
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Orlando, Florida • Tampa, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects

NCT01565681
View directory record Official record
Conditions
Pharmacokinetics of ASKP1240, Healthy Volunteers
Interventions
ASP1240, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2012 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SAD Study of IA-14069

NCT05317741
View directory record Official record
Conditions
Healthy
Interventions
IA-14069, Placebo
Drug
Lead sponsor
ILAb Co., Ltd.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects

NCT02460146
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
CXA-10, CXA-10 placebo
Drug · Other
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

NCT04092712
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects

NCT01818232
View directory record Official record
Conditions
Healthy
Interventions
[14C]-LX4211
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects

NCT01886209
View directory record Official record
Conditions
Drug Interactions
Interventions
Prednisone, VX-509, Methylprednisolone
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Cycling, Running, and Playing Rugby on Three Biomarkers That May Indicate Brain Injury

NCT06804291
View directory record Official record
Conditions
Healthy Male and Female Subjects
Interventions
Running, Cycling, Rugby, control group
Other
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boone, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lesinurad Interaction Study With Ranitidine

NCT01908257
View directory record Official record
Conditions
Healthy
Interventions
lesinurad 400 mg, ranitidine 150 mg, lesinurad 400 mg + ranitidine 150 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cefadroxil 500 mg Capsules Under Fasting Conditions

NCT00834275
View directory record Official record
Conditions
Healthy
Interventions
Cefadroxil 500 mg Capsules, DURICEF® capsules 500 mg
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293

NCT02126514
View directory record Official record
Conditions
Healthy Volunteers, Mass Balance Study
Interventions
AZD3293
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment

NCT02653014
View directory record Official record
Conditions
Healthy, Renal Insufficiency
Interventions
KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Evergreen Park, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects

NCT02063204
View directory record Official record
Conditions
Solid Tumours
Interventions
selumetinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection

NCT05203289
View directory record Official record
Conditions
Healthy
Interventions
BI 695501 - higher concentration, BI 695501 - lower concentration
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY2784544 in Healthy Male Subjects

NCT01577355
View directory record Official record
Conditions
Healthy Male Volunteers
Interventions
Drug
Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NSAID Drug Interaction Study

NCT01884272
View directory record Official record
Conditions
Gout
Interventions
lesinurad 400 mg, naproxen 250 mg, indomethacin 25 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function

NCT00674856
View directory record Official record
Conditions
Renal Failure
Interventions
naproxcinod
Drug
Lead sponsor
NicOx
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.

NCT07247942
View directory record Official record
Conditions
Healthy Subjects (HS)
Interventions
zidebactam administered as a 1g (approximately 200 μCi) IV infusion over 1 hour
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development of a Metabolic Assessment Tool for Chronic Kidney Disease

NCT01838239
View directory record Official record
Conditions
Immunoglobulin A Nephropathy, Healthy Subjects
Interventions
Fish Oil
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers

NCT03795519
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-olinciguat
Drug
Lead sponsor
Cyclerion Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

NCT01474330
View directory record Official record
Conditions
Healthy
Interventions
Pomalidomide, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

NCT03506854
View directory record Official record
Conditions
Renal Impairment
Interventions
ISIS 681257
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects

NCT00699777
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 50 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
4
States / cities
Gainesville, Florida • Miramar, Florida • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 13, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults

NCT01299805
View directory record Official record
Conditions
Healthy
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Sep 13, 2026, 10:35 PM EDT